​Our pipeline focuses on the discovery and development of precision TCR therapeutics for high-value oncology targets. By integrating computational modeling with experimental validation, Escalante is advancing novel therapies designed to selectively target cancer-driving antigens while expanding the reach of precision immunotherapy.